Ernexa Therapeutics Inc. (ERNA)
$4.20+$0.29 (+7.47%) Latest sessionExtended Hours
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 8 | 160,247 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
9 Form 4 filings on record, the earliest from Nov 5, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| James Arthur Bristol - Director | Grant or award | Stock Option (Right to buy) | 8,320 | $0.00 | - | |
| James Arthur Bristol - Director | Grant or award | Stock Option (Right to buy) | 5,083 | $0.00 | - | |
| Peter Cicala - Director | Grant or award | Stock Option (Right to buy) | 5,943 | $0.00 | - | |
| Peter Cicala - Director | Grant or award | Stock Option (Right to buy) | 5,083 | $0.00 | - | |
| David Polinsky - Director | Grant or award | Stock Option (Right to buy) | 5,083 | $0.00 | - | |
| William A. Wexler - Director | Grant or award | Stock Option (Right to buy) | 5,943 | $0.00 | - | |
| Elena Ratner - Director | Grant or award | Stock Option (Right to buy) | 5,944 | $0.00 | - | |
| Sanjeev Luther - Officer | Grant or award | Stock Option (right to buy) | 118,848 | $0.00 | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 4,000,000 | $12.50 | $2.00M | |
| Charles Cherington - 10% Owner | Open-market purchase | Warrants to Purchase Common Stock | 4,000,000 | - | - | |
| Sandra M. Gurrola - Officer | Option exercise | Common Stock | 30 | - | - | |
| Sandra M. Gurrola - Officer | Option exercise | Restricted Stock Units | 30 | $0.00 | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 261,756 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 4,768,783 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 1,237,762 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 5,420,823 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 1,562,988 | - | - | |
| Charles Cherington - 10% Owner | Other | Common Stock | 2,819,546 | $187.50 | $1.41M | |
| Charles Cherington - 10% Owner | Open-market purchase | 6.0% Senior Convertible Promissory Notes due 2028 | 0 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Warrants (right to buy) | 83,916 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | 6.0% Senior Convertible Promissory Notes due 2028 | 0 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Warrants (right to buy) | 83,916 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | 12.0% Senior Convertible Notes due September 24, 2025 | 0 | $513,234,750.00 | - | |
| Charles Cherington - 10% Owner | Other | 12.0% Senior Convertible Notes due September 24, 2025 | 0 | $0.00 | - | |
| Charles Cherington - 10% Owner | Open-market sale | 12.0% Senior Convertible Notes due December 12, 2028 | 0 | - | - | |
| Charles Cherington - 10% Owner | Open-market sale | 6.0% Senior Convertible Promissory Notes due 2028 | 0 | - | - | |
| Charles Cherington - 10% Owner | Open-market sale | Warrants (right to buy) | 523,512 | - | - | |
| Charles Cherington - 10% Owner | Open-market sale | Warrants (right to buy) | 2,475,524 | - | - | |
| Charles Cherington - 10% Owner | Open-market sale | Warrants (right to buy) | 3,125,976 | - | - |
Ernexa Therapeutics Inc. (ERNA) had 6 insider filings in the last 90 days, with the most recent on 2026-09-02. The full record for ERNA runs to 9 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ERNA were filed in the last 90 days. 12 purchases are on record for this company.
No insider sales of ERNA were filed in the last 90 days. 5 sales are on record for this company.
This page tracks ERNA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ERNA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
